PolyPid Ltd. (NASDAQ:PYPD) Forecasted to Earn Q1 2025 Earnings of ($0.81) Per Share

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for PolyPid in a research note issued to investors on Wednesday, May 1st. HC Wainwright analyst B. Pachaiyappan forecasts that the company will earn ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.

PolyPid Price Performance

Shares of NASDAQ:PYPD opened at $5.00 on Thursday. PolyPid has a 1-year low of $3.57 and a 1-year high of $13.48. The company’s fifty day moving average is $4.96 and its two-hundred day moving average is $5.02. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.83 and a quick ratio of 0.83.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.17) by ($1.80).

Institutional Trading of PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. bought a new position in shares of PolyPid Ltd. (NASDAQ:PYPD) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid accounts for approximately 1.8% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th largest holding. Rosalind Advisors Inc. owned 8.67% of PolyPid as of its most recent SEC filing. 26.47% of the stock is currently owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.